Authors: Clarke-Pearson, DL Van Le, L Iveson, T Whitney, CW Hanjani, P Kristensen, G Malfetano, JH Beckman, RA Ross, GA Lane, SR DeWitte, MH Fields, SZ

Citation: Dl. Clarke-pearson et al., Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer, J CL ONCOL, 19(19), 2001, pp. 3967-3975

Authors: Miller, DS Blessing, JA Kilgore, LC Mannel, R Van Le, L

Citation: Ds. Miller et al., Phase II trial of topotecan in patients with advanced, persistent, or recurrent uterine leiomyosarcomas - A Gynecologic Oncology Group study, AM J CL ONC, 23(4), 2000, pp. 355-357

Authors: Modesitt, SC Groben, PA Walton, LA Fowler, WC Van Le, L

Citation: Sc. Modesitt et al., Expression of Ki-67 in vulvar carcinoma and vulvar intraepithelial neoplasia III. Correlation with clinical prognostic factors, GYNECOL ONC, 76(1), 2000, pp. 51-55

Authors: Modesitt, SC Van Le, L

Citation: Sc. Modesitt et L. Van Le, Vulvar intraepithelial neoplasia III: Occult cancer and the impact of margin status on recurrence - Reply, OBSTET GYN, 93(4), 1999, pp. 633-634

Authors: Judson, PL He, XP Cance, WG Van Le, L

Citation: Pl. Judson et al., Overexpression of focal adhesion kinase, a protein tyrosine kinase, in ovarian carcinoma, CANCER, 86(8), 1999, pp. 1551-1556

Authors: Gehrig, PA Van Le, L Olatidoye, B Geradts, J

Citation: Pa. Gehrig et al., Estrogen receptor status, determined by immunohistochemistry, as a predictor of the recurrence of stage I endometrial carcinoma, CANCER, 86(10), 1999, pp. 2083-2089